The American pharmaceutical company Moderna recorded losses of 1,301 million dollars (around 1,190 million euros) between January and June, far from the 5,854 million dollars (5,355 million euros at current exchange rates) that it had achieved in the first half of 2022 thanks to the sales its Covid-19 vaccine.
With the pandemic under control and vaccine sales falling as a result, Moderna posted sales of $2,206 million for the first six months of the year, compared to $10,815 million a year ago.
In the second quarter, the most estimated by Wall Street analysts, Company based in New York It posted losses of $1,380 million compared to profits of $2,197 million in 2022 and revenue of $344 million, down 92% year-on-year.
Moderna accuses the end of nationwide vaccination against Covid-19
However, the company said that this year’s Covid-19 vaccine revenue would come in better than expected despite the sharp fall in vaccine sales in the second quarter.
Moderna CEO Stéphane Bancel noted in a statement that second-quarter sales were “on track given the seasonal nature of Covid-19.”
“Our late-stage clinical product pipeline is in full swing with four Phase 3 infectious disease vaccines, including RSV, which recently received regulatory approval. Our individualized neoantigen therapy for melanoma is now in phase 3 and our lead rare disease program for PA is in dose confirmation,” noted Bancel.
In premarket trading, shares of Moderna lost 0.65%.